Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells

doi:10.1111/j.1440-1681.2010.05395.x

CORC > 兰州大学 > 兰州大学 > 基础医学院 > 期刊论文

	Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells
	Zhang, XY; Yeung, ED; Wang, JY; Panzhinskiy, EE; Tong, C; Li, WG; Li, J; Li, J (reprint author), SUNY Buffalo, Dept Pharmacol & Toxicol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA.
刊名	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
	2010-08
卷号	37 期号:8 页码:841-847
关键词	AMP-activated protein kinase isoliquiritigenin prostate cancer cells reactive oxygen species
ISSN号	1440-1681
DOI	10.1111/j.1440-1681.2010.05395.x
文献子类	Article
英文摘要	P>1. Isoliquiritigenin (ISL) is a simple chalcone-type flavonoid derived from liquorice compounds. It has been reported to have anti-oxidative and antitumour activities. The aim of the present study was to investigate the antitumour effect of ISL on prostate cancer cells and to explore the possible signalling mechanisms involved. 2. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The fluorescent probe 2',7'-dichlorofluorescein diacetate (H2DCF-DA) was used to measure intracellular levels of reactive oxygen species (ROS). Mitochondrial membrane potential (Psi(m)) was measured using the mitochondrial probe 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide (JC-1). 3. Isoliquiritigenin treatment (10-100 mu mol/L for 24 h) markedly inhibited the proliferation of both C4-2 and LNCaP prostate cancer cells in a dose-dependent manner. Intriguingly, ISL treatment (10-100 mu mol/L for 24 h) had no effect on the viability of IEC-6 normal epithelial cells. Treatment of C4-2 and IEC-6 cells with 87.0 mu mol/L ISL significantly decreased ROS levels and the Psi(m) of C4-2 cells, but had no effect on either parameter in IEC-6 cells. Furthermore, AMP-activated protein kinase (AMPK) and extracellular-signal regulated kinase (ERK) levels were three to fourfold higher in IEC-6 cells than in C4-2 cells (P < 0.05). 4. The results of the present study suggest that ISL, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer C4-2 cells, which may be attributed, in part, to defective AMPK and ERK signalling pathways in C4-2 compared with IEC-6 cells.
学科主题	Pharmacology & Pharmacy ; Physiology
出版地	HOBOKEN
资助项目	国家自然科学基金项目 ; 国家留学基金委项目 ; 甘肃省自然科学基金计划 ; 美国国立卫生研究院项目
项目编号	China Scholarship Council ; Gansu Province Natural Science Foundation of China [0710RJZA037] ; National Institutes of Health IDeA Network for Biomedical Research Excellence (INBRE) [5P20RR016474] ; American Heart Association [SDG0835168N] ; American Federation for Ageing [08007] ; National Center for Research Resources [1UL1RR025014-01]
语种	英语
WOS记录号	WOS:000280457100011
资助机构	NSFC ; CSC ; GSSTD ; NIH
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/121453]
专题	基础医学院_期刊论文
通讯作者	Li, J (reprint author), SUNY Buffalo, Dept Pharmacol & Toxicol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA.
推荐引用方式 GB/T 7714	Zhang, XY,Yeung, ED,Wang, JY,et al. Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells[J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,2010,37(8):841-847.
APA	Zhang, XY.,Yeung, ED.,Wang, JY.,Panzhinskiy, EE.,Tong, C.,...&Li, J .(2010).Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells.CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,37(8),841-847.
MLA	Zhang, XY,et al."Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells".CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY 37.8(2010):841-847.